Holen Sie sich die Stockscreener-App
26.34
0.53%
0.14
Handel nachbörslich:
26.20
-0.14
-0.53%
Schlusskurs vom Vortag:
$26.20
Offen:
$26.51
24-Stunden-Volumen:
1.92M
Relative Volume:
0.40
Marktkapitalisierung:
$19.56B
Einnahmen:
$956.00K
Nettoeinkommen (Verlust:
$-221.32M
KGV:
-82.31
EPS:
-0.32
Netto-Cashflow:
$-142.25M
1W Leistung:
+3.70%
1M Leistung:
+28.11%
6M Leistung:
+19.19%
1J Leistung:
+199.83%
1-Tages-Spanne:
$26.23
$27.25
1-Wochen-Bereich:
$24.09
$28.62
52-Wochen-Spanne:
$8.80
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
26.34 | 18.86B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich - Yahoo Finance
3 Monster Stocks in the Making to Buy Right Now - The Globe and Mail
3 Monster Stocks in the Making to Buy Right Now - The Motley Fool
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com
Is Summit Therapeutics Inc. a good long term investmentExceptional gains - Autocar Professional
Summit Therapeutics PLC (NASDAQ:SMMT) Shares Acquired by Cerity Partners LLC - Defense World
Summit Therapeutics Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
What drives Summit Therapeutics Inc. stock priceFree Investment Community - jammulinksnews.com
What analysts say about Summit Therapeutics Inc. stockHigh-return market picks - Autocar Professional
Published on: 2025-07-19 02:49:19 - jammulinksnews.com
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Investors to Reach Out - ACCESS Newswire
Principal Financial Group Inc. Has $4.75 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World
Summit Therapeutics: Not Entirely Positive HARMONi Data And Partnership Rumors (SMMT) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Stockholders to Reach Out - ACCESS Newswire
10 Stocks Exploding Higher: Bitcoin Miners Dominate the List - Insider Monkey
how summit therapeutics inc. stock performs during market volatilityAnalyst Grade Signals - Newser
Summit Therapeutics Jumps 16% On Heavy Volume As Technicals Signal Bullish Breakout - AInvest
Summit Therapeutics Inc (SMMT) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Summit Therapeutics Explodes 12%: Legal Probe Ignites Volatility Amid Regulatory Crosshairs - AInvest
Summit Therapeutics Soars 16.5% Amid Regulatory Crossroads and Whale Activity - AInvest
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
What makes Summit Therapeutics Inc. stock price move sharplyFree Predictions - Newser
H.C. Wainwright Keeps Their Buy Rating on Summit Therapeutics (SMMT) - The Globe and Mail
Why Summit Therapeutics Inc. stock attracts strong analyst attentionFree Trading Group - Newser
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm - FinancialContent
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - WV News
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal - MSN
Where are the Opportunities in (SMMT) - news.stocktradersdaily.com
10 Stocks Going Wild - Insider Monkey
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal - Insider Monkey
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca - Yahoo Finance
Pomerantz LLP Investigates Claims Against Summit Therapeutics Inc. - AInvest
Summit Therapeutics: A $15B Oncology Gamble with Ivonescimab - AInvest
Summit Therapeutics' $15 Billion Gamble: Balancing Hope and Hurdles in Lung Cancer Therapeutics - AInvest
AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report - NewsBreak: Local News & Alerts
AstraZeneca and Summit Therapeutics: A $15 Billion Gamble on Lung Cancer's Next Breakthrough? - AInvest
Why Summit Therapeutics Stock Soared 8% Higher Today - Nasdaq
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment - Benzinga
AstraZeneca Discusses $15 Billion Partnership With Summit Therapeutics, Bloomberg Says, Citing Sources - MarketScreener
Summit Therapeutics’ Stock Surges Amid AstraZeneca Talks - TipRanks
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):